Neurology prior authorization at Humana
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Humana neurology PA at a glance
Humana reviews neurology PA submissions against its medical policy library, with rules drawn primarily from AAN (American Academy of Neurology) + AHS (American Headache Society) for migraine. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet — what to send
- MS or migraine diagnosis with ICD-10
- MS: MRI brain/spine within 6-12 months
- Migraine: headache diary (paper or app) covering ≥3 months
- Prior preventives with drug, dose, duration, and reason for discontinuation
- Disease severity score (EDSS for MS; MIDAS/HIT-6 for migraine)
Common denial patterns to pre-empt
Patterns observed in neurology across payers, and where Humana's book of business overlaps:
- MS: McDonald criteria not documented
- MS: step therapy through DMTs before high-efficacy
- Migraine: insufficient prior preventive trials (typically 2 from different classes)
- Migraine: monthly migraine day frequency not documented
- Functional impairment / disability not characterised
- MA plan step therapy on Part B drugs
- Prior auth on specialty drugs
Appeal angles when Humana denies
- AAN guideline citation by year
- MRI documentation of new lesions / clinical relapse for MS
- Headache diary documenting ≥4 monthly migraine days for CGRP class
- Failed step-therapy preventives with dose/duration/AE for each
Peer-to-peer prep
- Pull the most recent MRI report (lesion count, T2/FLAIR burden, new enhancement)
- Quote the AAN practice advisory by year
- For migraine: bring headache diary entries — payers reject 'frequent migraines' without quantified MMDs
- For high-efficacy MS DMTs: state explicitly which DMTs were tried and the failure (relapse, MRI activity, AE)
Drug-specific PA criteria at Humana
Deep dives on each drug's PA criteria at Humana:
Frequently asked questions
What documentation does Humana need for neurology prior authorizations?
Humana's PA packet for neurology typically includes: MS or migraine diagnosis with ICD-10; MS: MRI brain/spine within 6-12 months; Migraine: headache diary (paper or app) covering ≥3 months; Prior preventives with drug, dose, duration, and reason for discontinuation. AAN (American Academy of Neurology) + AHS (American Headache Society) for migraine citations strengthen the submission.
What's the turnaround at Humana?
Humana standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Medicare Advantage extension rule under 42 CFR Part 422 may add 14 days. Internal appeal window if denied: 60 days.
Which neurology drugs does Humana most often PA-restrict?
Top targets in neurology: ocrelizumab, natalizumab, ofatumumab, erenumab, galcanezumab. Each follows the per-drug step therapy + documentation requirements published in Humana's medical policy library.
How do I prep a peer-to-peer with Humana in neurology?
Pull the most recent MRI report (lesion count, T2/FLAIR burden, new enhancement) Quote the AAN practice advisory by year Have the policy URL and the patient's chart open before the call.
Generate a Neurology PA packet
Open ApprovalHelp — generate a neurology PA packet tailored to Humana's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com